Page last updated: 2024-12-10
ro26-4550
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5288250 |
| CHEMBL ID | 419362 |
| SCHEMBL ID | 14136720 |
| MeSH ID | M0449668 |
Synonyms (15)
| Synonym |
|---|
| bdbm50147974 |
| (s)-2-[2-((r)-1-carbamimidoyl-piperidin-3-yl)-acetylamino]-3-(4-phenylethynyl-phenyl)-propionic acid methyl ester |
| 2-[3-methyl-4-(n-methyl-guanidino)-butyrylamino]-3-(4-phenylethynyl-phenyl)-propionic acid methyl ester |
| methyl n-{[(3r)-1-carbamimidoyl-3-piperidinyl]acetyl}-4-(phenylethynyl)-l-phenylalaninate |
| 1M48 |
| DB03453 |
| methyl (2s)-2-[[2-[(3r)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate |
| NCGC00166396-01 |
| ro-264550 |
| CHEMBL419362 , |
| SCHEMBL14136720 |
| methyl n-{[(3r)-1-carbamimidoylpiperidin-3-yl]acetyl}-4-(phenylethynyl)-l-phenylalaninate |
| Q27460411 |
| PD070751 |
| AKOS040749349 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Interleukin-2 receptor subunit alpha | Mus musculus (house mouse) | IC50 (µMol) | 6.0000 | 0.0600 | 3.0300 | 6.0000 | AID91893 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, interleukin-2 | Homo sapiens (human) | Kd | 8.2000 | 8.2000 | 8.2000 | 8.2000 | AID977611 |
| Interleukin-2 receptor subunit alpha | Mus musculus (house mouse) | EC50 (µMol) | 100.0000 | 0.0030 | 0.0030 | 0.0030 | AID107966 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID91897 | Dissociation constant for mouse Interleukin-2 receptor alpha by SPR assay | 2004 | Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12 | Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. |
| AID107966 | Effective concentration required against phosphorylation of Mammary gland factor/STAT5 | 2004 | Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12 | Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. |
| AID700921 | Inhibition of IL2 receptor binding to IL2 alpha receptor by scintillation proximity assay | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Chemical modulators working at pharmacological interface of target proteins. |
| AID91893 | Inhibition of mouse Interleukin-2 receptor alpha | 2004 | Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12 | Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions. |
| AID241068 | Inhibitory concentration against interleukin-2 binding | 2005 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4 | Identification of nonpeptidic small-molecule inhibitors of interleukin-2. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2003 | Proceedings of the National Academy of Sciences of the United States of America, Feb-18, Volume: 100, Issue:4 | Binding of small molecules to an adaptive protein-protein interface. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2003 | Proceedings of the National Academy of Sciences of the United States of America, Feb-18, Volume: 100, Issue:4 | Binding of small molecules to an adaptive protein-protein interface. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||